Senile plaques consisting of b-amyloid (Ab) and neurofibrillary tangles composed of hyperphosphorylated tau are major pathological hallmarks of Alzheimer's disease (AD). Elucidation of factors that modulate Ab generation and tau hyperphosphorylation is crucial for AD intervention. Here, we identify a mouse gene Rps23r1 that originated through retroposition of ribosomal protein S23. We demonstrate that RPS23R1 protein reduces the levels of Ab and tau phosphorylation by interacting with adenylate cyclases to activate cAMP/PKA and thus inhibit GSK-3 activity. The function of Rps23r1 is demonstrated in cells of various species including human, and in transgenic mice overexpressing RPS23R1. Furthermore, the AD-like pathologies of triple transgenic AD mice were improved and levels of synaptic maker proteins increased after crossing them with Rps23r1 transgenic mice. Our studies reveal a new target/pathway for regulating AD pathologies and uncover a retrogene and its role in regulating protein kinase pathways.
INTRODUCTION
Alzheimer's disease (AD) is featured by extracellular neuritic plaques, intracellular neurofibrillary tangles (NFTs), synaptic dysfunctions, and neural degeneration in vulnerable brain regions (Tanzi and Bertram, 2005) . Neuritic plaques are composed of aggregates of heterogeneous b-amyloid (Ab) peptides, which are derived from b-amyloid precursor protein (APP) through sequential cleavages by b-secretase (BACE1) and the g-secretase complex (consisting of at least four components: presenilin, nicastrin, APH-1, and PEN-2) (Cole and Vassar, 2007; De Strooper, 2003; . Multiple lines of evidence suggest that overproduction/aggregation of Ab in the brain is a causative factor for AD pathogenesis (Hardy and Selkoe, 2002) . NFTs are composed of hyperphosphorylated microtubule-associated protein tau (Buee et al., 2000; Lee et al., 2001) . Numerous studies have shown that pathogenic APP metabolism/Ab generation and tau phosphorylation are highly regulated via various signal transduction pathways, e.g., protein kinases and phosphatases (Buxbaum et al., 1994; Fang et al., 2000; Xu et al., 1996) and steroid and peptide hormones (Gasparini et al., 2001; Xu et al., 1998) . Among these regulatory pathways, glycogen synthase kinase-3 (GSK-3, a and b isoforms), a serine/threonine kinase essential for a variety of cellular functions including cell adhesion, cell division, transcription (Frame and Cohen, 2001) , has been demonstrated to regulate both Ab generation and tau phosphorylation (Flaherty et al., 2000; Phiel et al., 2003) . This unique feature renders manipulation of GSK-3 activity an attractive therapeutic approach for AD (Frame and Cohen, 2001; Martinez et al., 2002; Medina and Castro, 2008) . Hence identification of new genes involved in these processes will be instrumental in developing novel AD therapeutics.
The creation of genetic novelty by the formation of new genes has an important role in evolution. New genes can originate through different mechanisms that include exon shuffling, gene duplication, gene fusion/fission, mobile element integration, lateral gene transfer, and retroposition (Long et al., 2003) . Retroposition is a process in which a parental mRNA is reversetranscribed and inserted into the organism's genome, creating duplicate genes in new genomic positions (Hollis et al., 1982; Karin and Richards, 1982; Ueda et al., 1982) . Although these intronless retroposed gene copies commonly lack the regulatory elements of parental genes and thus routinely have been classified as processed pseudogenes (Jeffs and Ashburner, 1991; Mighell et al., 2000; Zhang et al., 2004) , occasionally, these retroposed gene copies can recruit regulatory elements as well as protein-encoding sequences at or near the retroposition site and become expressed and functional (Babushok et al., 2007; Kaessmann et al., 2009; Long et al., 2003; Vinckenbosch et al., 2006) . Nevertheless, studies to elucidate the functions of these newly originated genes, especially the functions related to diseases, are limited (Kaessmann et al., 2009; Vinckenbosch et al., 2006) .
Random homozygous gene perturbation (RHGP; previously called random homozygous knockout, RHKO) is a genomewide genetic approach that identifies genes based on their biological functions (Li and Cohen, 1996; Liu et al., 1999 Liu et al., , 2000a Liu et al., , 2000b . The design of RHGP enables either reduced or increased expression of chromosomal genes near the incorporation site of the gene search vector cassette that contains a regulated promoter. This strategy has been used successfully to identify genes whose functional homozygous inactivation leads to reversible tumorigenesis (Li and Cohen, 1996; Liu et al., 1999 Liu et al., , 2000a Liu et al., , 2000b or altered sensitivity to chemotherapeutic agents (Lih et al., 2006) .
Here, using the RHGP approach, we identified a gene Rps23r1 that originated through retroposition of the mouse ribosomal protein S23 (Rps23) mRNA. The Rps23r1 gene is reversely transcribed relative to its parental gene, expressing a structurally unrelated yet functional protein RPS23R1. More importantly, we demonstrated both in vitro and in vivo that overexpression of the RPS23R1 protein decreases the levels of Ab and tau phosphorylation and increases synaptic marker proteins in AD transgenic mice by inhibiting GSK-3 activity via the adenylate cyclase/ protein kinase A (PKA) pathway.
RESULTS

Genome-wide Screening for Genes that Regulates Ab Generation
It has been shown that reduction of Ab levels is accompanied by cell-surface accumulation of APP bCTF (the product of b-cleavage and immediate substrate for g-cleavage), which is readily detectable in cells deficient in PS1 (Chen et al., 2000) , and these cells can be identified using an antibody specifically recognizing the N terminus of APP bCTF (FCA18) (Ancolio et al., 1999) . Based on this observation, we adapted RHGP as a high throughput screen to search for genes that regulate Ab generation.
We modified the original vector pLLGSV (Li and Cohen, 1996) to increase efficiency of retroviral integration and gene recovery. The new RHGP gene search vector contains modified LTRs and utilizes the Cre-LoxP mediated recombination to minimize promoter interference in provirus and to facilitate genomic DNA cloning ( Figure 1A ). This vector was transfected into Phoenix-Ampho cells for viral packaging. Harvested retrovirus was used to infect mouse neuroblastoma N2a cells stably expressing the human APP Swedish mutation (N2aSwe). After random insertion, the provirus ( Figure 1B ) expressed Cre recombinase for recognition and recombination of the two LoxP sites located in the 5 0 LTR and 3 0 LTR, respectively, generating the final integrated provirus ( Figure 1C) . A tetracycline regulated promoter (TRE-CMV) promoter in the final integrated provirus drives the expression of Pac for puromycin selection and initiates transcription into flanking chromosomal gene that can either overexpress, when TRE-CMV is in the same orientation, or suppress (by expressing antisense transcripts) when TRE-CMV is in the opposite orientation relative to the flanking gene. Moreover, transcription of the tetracycline-regulated (tet-off) transactivator was reversed in the presence of tetracycline (or doxycycline).
Therefore, we first acquired N2aSwe cells with stable integration of the RHGP search vector by puromycin selection. These cells were live-immunostained with fluorescently labeled FCA18 antibody followed by multiple rounds of FACS sorting to enrich for cells showing surface APP bCTF accumulation. Less than 0.1% of cells showing bCTF accumulation after first round of FACS sorting were enriched up to 75% following another two rounds of FACS sorting ( Figure 2A) . These cells were then sorted with additional FACS in the presence of doxycycline for a reversion of cell surface APP bCTF to background level to eliminate potential false positive. The final sorted cells were cloned individually, propagated and assayed for both accumulated cell surface APP bCTF and reduced Ab generation. This screening strategy is shown in Figure 1D .
Identification of the Rps23r1 Gene One clone, FG01, was isolated for the high level of cell-surface APP bCTF and the significant reduction of Ab secretion ( Figures  2B and 2C ). Both phenotypes were reversed by doxycycline treatment, validating that the effects were indeed a result of RHGP rather than cell-cell/clonal variation in APP/bCTF expression or any random mutagenesis ( Figure 2C ). Subcloning and sequence analyses revealed that the RHGP vector was inserted into chromosome 8 at a site $1.2 kb upstream of the C330021F23Rik gene (GenBank ID: 546049), which has no known function. We herein designated this gene as Rps23r1 based on its origination (see below). The upstream location and the same orientation of the inserted RHGP vector strongly suggested that Rps23r1 was likely overexpressed in the FG01 cell clone. This notion was supported by real-time reverse transcription-PCR (RT-PCR) using RNAs from parental N2aSwe and the FG01 RHGP cell clone, which showed that Rps23r1 was overexpressed in the FG01 RHGP cell clone and its overexpression was reversed by doxycycline treatment ( Figure 2D ). The Rps23r1 gene is predicted to encode a 141 amino acid-long hypothetical protein that we designate RPS23R1. Interestingly, analyses of multiple genome databases (GenBank, UCSC Genome Browser, and Ensemble Genome Browser) with the RPS23R1 protein sequence identified another three homologous proteins in mice but no obvious homologs in humans and rats (data not shown). Further analysis with the Rps23r1 gene sequence showed that the predominant protein-encoding region (Barelli et al., 1997) and screened by multiple rounds of FACS sorting. Less than 0.1% of cells showing bCTF accumulation after first round of FACS sorting were enriched up to 75% following another two rounds of FACS sorting. y axis, cell number; x axis, fluorescence intensity. (B) Parental N2aSwe cells (I and III) and one cell clone derived from FACS sorting, FG01 (II and IV), were live immunostained to visualize surface APP bCTF (red, I and II). Cells were also double immunostained with FITC-VVA (Vicia Vilosa Agglutinin, Vector Laboratories) to stain total surface glycoproteins (III and IV). (C) Parental N2aSwe and FG01 cells were treated with or without 2 mg/ml doxycycline (DOX) for 72 hr. Equal amounts of cell lysates were subjected to SDS-PAGE and western blot to detect full-length APP and bCTFs. Secreted Ab was immunoprecipitated from conditioned media and analyzed by western blot. Levels of these proteins in FG01 cells were quantified by densitometry and normalized to those in controls for comparison (set as one arbitrary unit). (D) Parental N2aSwe and FG01 cells were treated with 2 mg/ml doxycycline (+) or DMSO (À) for 72 hr before RNA was isolated for real-time reverse transcription-PCR to quantify Rps23r1 expression. The level of Rps23r1 in N2aSwe cells treated with DMSO was used as normalization controls (set as one arbitrary unit). *p < 0.05. p values were calculated using two-tailed Student's t test (n = 3). Error bars, SEM. of the Rps23r1 gene was highly homologous to the reverse and complementary sequence of the mouse ribosomal protein S23 (Rps23) mRNA ( Figure 3A) . The similarity between Rps23r1 and mouse Rps23 was even higher than those between mouse Rps23 and rat or human Rps23 ( Figure 3B ), suggesting that Rps23r1 originated from mouse Rps23 after the divergence of mice and rats. New genes can originate through different mechanisms (Long et al., 2003) . However, the presence of the mouse Rps23 untranslated regions (UTRs) and the absence of the mouse Rps23 introns in the homologous regions between Rps23r1 and mouse Rps23 clearly suggest that Rps23r1 originated through retroposition of the mouse Rps23 mRNA, which recruited regulatory units and additional protein-encoding sequence near the retroposition site. But transcription of Rps23r1 is reversed compared to Rps23. To search for human homologs of Rps23r1, we scanned the human genome with the human Rps23 cDNA sequence and identified several Rps23 retroposition sites (see Figure S1 available online). However, computational gene prediction of these sites revealed no functional Rps23r1-like genes. We also carried out RT-PCR with primers binding regions right next to these human Rps23 retroposition sites and failed to obtain positive amplification (data not shown).
RPS23R1 Is a Type Ib Transmembrane Protein
Bioinformatics analysis using the RPS23R1 amino acid sequence predicted a helical transmembrane domain near the C terminus but no obvious signal peptide sequence. We constructed a vector expressing recombinant RPS23R1 with a Myc tag at the N terminus and a His 6 tag at the C terminus (Myc-RPS23R1-His 6 ; Figure 4A ). Both Myc and His 6 antibodies recognized a product of approximately 17 kDa in transfected Myc-RPS23R1-His 6 cells, consistent with the predicted molecular weight, indicating that there is no cleavable signal peptide sequence within RPS23R1 ( Figure 4B ). Furthermore, after transfection of Myc-RPS23R1-His 6 vector into N2a cells, fractionation of cell lysates into cytosolic and membrane components indicated that the majority of RPS23R1 protein was located in membrane fractions ( Figure 4C ). Biotinylation assays also revealed that RPS23R1 was delivered to the cell surface ( Figure 4D ). To determine RPS23R1 topology, we transfected N2a cells with the Myc-RPS23R1-His 6 vector and immunostained either live cells or cells after permeabilization, using antibodies against Myc or His 6 . Our results show that although both antibodies were immunoreactive in permeabilized cells, only the Myc antibody positively stains the membranes of live cells, whereas the His 6 antibody does not, suggesting that the RPS23R1 N terminus is extracellular ( Figure 4E ). Hence these results suggest that RPS23R1 is a type Ib transmembrane protein that has a normal type I transmembrane protein orientation but no cleavable signal peptides. Immunoprecipitation combined with live immunostaining also confirmed the type Ib transmembrane topology of RPS23R1 ( Figure S2 ). We derived an antibody against the N terminus of RPS23R1 ( Figure S3 ) . Additional gene parts of Rps23r1 recruited from integrated chromosomal sites were indicated by lines (for introns) and boxes (for exons) (not drawn to proportion). The colors red, green, and blue indicate exons, introns, and protein-encoding regions, respectively. *nonconserved nucleotide residues. (B) Phylogenetic relationships of Rps23r1 and human, rat, and mouse Rps23 genes (hRps23, rRps23, and mRps23) based on their sequence identity to mRps23 within the homologous region. and using this antibody for immunoprecipitation followed by western blot analysis, we confirmed expression of RPS23R1 in both cortex and hippocampus ( Figure 4F ). In situ hybridization analysis of Rps23r1 expression in mouse brain revealed that Rps23r1 is expressed primarily in hippocampus, dentate gyrus, and cortex ( Figure 4G ).
RPS23R1 Overexpression Reduces Ab Levels, GSK-3 Activity, and Tau Phosphorylation
The FG01 RHGP cell clone exhibits increased APP bCTF accumulation and reduced Ab levels ( Figure 2C ), suggesting that RPS23R1 regulates APP processing. To corroborate this, we overexpressed RPS23R1 in N2aSwe cells. The results showed that, although the levels of total APP were not affected, the levels of extracellular and intracellular Ab were significantly reduced by RPS23R1 overexpression, and the levels of bCTF and sAPPa were significantly increased ( Figure 5A ). When human HeLa cells stably expressing the human APP Swedish mutation (HeLaSwe) were transfected with mouse RPS23R1, we also observed reduced Ab levels and increased accumulation of bCTF and sAPPa ( Figure 5A ). ELISA analysis confirmed that both Ab40 and Ab42 levels were significantly reduced following RPS23R1 expression in HeLaSwe cells ( Figure 5B ). These data demonstrated that mouse RPS23R1 can function not only in mouse cells, but also in human cells.
To determine whether RPS23R1 reduces Ab levels by modulating b-secretase activities, we examined b-secretase (BACE1) activity and the protein level of BACE1 in vitro in RPS23R1-overexpressing cells and found them both unchanged ( Figures S4A and S4B) . APP bCTF accumulation can also be attributed to a decrease in g-secretase-mediated cleavage. However, cleavage of Notch, another important g-secretase substrate (Kopan and Goate, 2000) , was not altered by RPS23R1 overexpression ( Figure S4C ). Protein levels of nicastrin, an important component of the g-secretase complex, and ADAM10 and TACE, two putative a-secretases , were also not affected by RPS23R1 overexpression ( Figure S4B ).
Although the possibility that RPS23R1 may modulate substrate specificity or accessibility to g-secretase cannot be (A) Scheme of the RPS23R1 construct used in this study (not drawn to proportion), with a Myc tag at the N terminus and a His 6 tag at the C terminus. RPS23R1 has a predicted single transmembrane domain (TM) near its C terminus. (B) The Myc-RPS23R1-His 6 vector (RR1) or a pcDNA control (Con) was transiently transfected into N2a cells. Cell lysates were subjected to western blot (WB) with antibodies against Myc or His 6 . (C) RPS23R1 (RR1), APP, and SMAD3 plasmids (all Myc tagged) were individually transfected into N2a cells. After fractionation of membrane and cytosol, equal volumes of samples from both fractions were subjected to SDS-PAGE and western analysis with a Myc antibody. *nonspecific band. (D) After RPS23R1 transfection, N2a cells were biotinylated and biotin-labeled membrane proteins were affinity precipitated (AP) with streptivadin and immunoblotted with a Myc antibody. (E) After transfection with the Myc-RPS23R1-His 6 construct, N2a cells were either live immunostained or permeabilized and immunostained with Myc or His 6 antibody. Cells were then fixed, permeabilized, incubated with Alexa Fluor 488-conjugated secondary antibody and DAPI, and examined by immunofluorescence microscopy. Red arrows indicate membrane staining of RPS23R1 in live cells. (F) Equal protein lysates from mouse cortex and hippocampus (hippo) were incubated with an RPS23R1 antibody (+) or rabbit IgG (À). After immunoprecipitation, samples were subjected to SDS-PAGE and western blot analysis with the RPS23R1 antibody. (G) An antisense probe of Rps23r1 and the corresponding sense probe (as control) were used for in situ hybridization in brain sections from a twomonth-old C57Bl6 mouse. Red arrows indicate Rps23r1 expression. excluded, it is equally possible that RPS23R1 regulates other proteins/pathways functioning in APP processing and Ab generation. One of those could be GSK-3, which has been shown to affect Ab generation (without affecting g-secretase-mediated Notch cleavage) and tau phosphorylation (Phiel et al., 2003; Takashima et al., 1995) . Thus, we studied the activities of GSK-3a/b in the presence or absence of RPS23R1 overexpression by examining levels of phospho-GSK-3a (Ser 21) and phospho-GSK-3b (Ser 9) (which represent inactivated forms of GSK-3) and by in vitro kinase assays. In cells overexpressing RPS23R1 we observed that GSK-3a/b was more highly phosphorylated at these sites in mouse N2aSwe ( Figure 5A ), rat PC12 (data not shown), and human HeLaSwe ( Figure 5A ) and HEK293 (data not shown) cells, indicating that RPS23R1 can decrease GSK-3 kinase activity in cells of various types and species including human. In vitro kinase assays also demonstrated an approximately 50% decrease in GSK-3a and a 40% decrease in GSK-3b activities in RPS23R1-overexpressing cells ( Figure 5C ). Remarkably, in the presence of lithium, a general inhibitor of both GSK-3a and GSK-3b, RPS23R1 overexpression could not further reduce GSK-3a/b activity or Ab production ( Figure 5D ). These data suggest that RPS23R1 reduces Ab levels by downregulating GSK-3 activity.
GSK-3 is a major kinase that phosphorylates tau in AD (Flaherty et al., 2000) . Hence, we asked whether RPS23R1 affects tau phosphorylation by inhibiting GSK-3. We cotransfected N2aSwe cells with the human tau splice variant T40 and with RPS23R1 (or control vectors) and examined tau phosphorylation at the threonine 205 site (pT205) and the PHF-1 tau epitope sites (serine 396 and serine 404), which are GSK-3 phosphorylation targets and the major paired helical filament (PHF) sites found in NFTs. Overexpression of RPS23R1 significantly decreased tau phosphorylation at these GSK-3 target sites and increased unphosphorylated tau levels without affecting total tau levels Conditioned media were assayed for Ab. Cell lysates were analyzed for total and phosphorylated GSK-3a/b and for RPS23R1. (E) N2a cells were transfected with human tau, equally split, and transfected with RPS23R1 (RR1) or control vector (Con). The levels of phosphorylated tau including threonine 205 (pT205) and PHF-1, unphopshorylated tau (Tau-1), total tau, and RPS23R1 were analyzed. In some experiments, protein levels were quantified by densitometry and normalized to those of controls for comparison (set as one arbitrary unit). Error bars indicate SEM *p < 0.05, **p < 0.01. p values were calculated using two-tailed Student's t test (n = 3).
( Figure 5E ). These results suggest a role for RPS23R1 in reducing tau phosphorylation, in addition to its effect on Ab levels. We also analyzed protein levels and activity of CDK5, another kinase mediating tau phosphorylation in AD (Flaherty et al., 2000) , following RPS23R1 overexpression and observed little change, suggesting that CDK5 is not involved in RPS23R1-regulated tau phosphorylation ( Figure S5 ).
RPS23R1 Interacts with Adenylate Cyclases to
Upregulate cAMP Levels and PKA Activity Inhibition of GSK-3 activity via phosphorylation of serine 21 in GSK-3a and serine 9 in GSK-3b can be mediated by protein kinase A (PKA) (Fang et al., 2000) , so we studied whether RPS23R1 regulates PKA activity. In vitro kinase assays revealed that RPS23R1-transfected cells had significantly more PKA activity than control cells ( Figure 6A) , consistent with the observation that RPS23R1 overexpression increased phosphorylation of CREB, a PKA substrate ( Figure 6B ). In addition, RPS23R1 failed to inhibit GSK-3 activity and Ab generation when PKA activity was suppressed by the specific inhibitor H89 ( Figure 6B ). Furthermore, downregulation of endogenous RPS23R1 expression in N2aSwe cells by RNA interference (Figures 6C and 6D ) dramatically reduced CREB phosphorylation, and increased GSK-3 activity and Ab generation ( Figure 6D ). These data indicate that RPS23R1's effects on GSK-3 activity and Ab levels require PKA activation. Moreover, increased sAPPa secretion upon RPS23R1 overexpression ( Figure 5A ) is also likely due to PKA activation, because PKA can stimulate budding of APPcontaining vesicles from the trans-Golgi network (TGN) to cell surface, the major site for APP cleavage by a-secretase, therefore facilitating sAPPa generation (Xu et al., 1996) .
Since cAMP binds to and activates PKA (Taylor et al., 2008) , we investigated whether RPS23R1 overexpression had any effect on cAMP levels. We found that RPS23R1 overexpression significantly increased cAMP levels in both mouse N2a (38%) and rat PC12 (75%) cells ( Figure 6E ). We next examined potential Results were normalized to control values (set as one arbitrary unit). (B) After transfection with RPS23R1 (RR1) or control vector (Con) and equal splitting, cells were treated with DMSO (control) or the PKA inhibitor H89. Conditioned media were analyzed for Ab and cell lysates were analyzed for phosphorylated and total CREB, phosphorylated and total GSK-3, and RPS23R1 levels. (C) N2aSwe cells were transfected with Rps23r1-specific RNAi or a scrambled RNAi (SC). Total RNA was then extracted and subjected to RT-PCR. The mRNA level of Rps23r1 relative to that of b-actin was analyzed and normalized to that from scrambled RNAi-transfected cells (set as one arbitrary unit). (D) After RNAi of Rps23r1 (RR1) expression, conditioned media from N2aSwe cells were analyzed for Ab, and cell lysates were analyzed for endogenous RPS23R1 and phosphorylated/total CREB and GSK-3. (E) Mouse N2a and rat PC12 cells were transfected with RPS23R1 or control vector (Con), and cell lysates were assayed for cAMP levels. Data were normalized to control values (as one arbitrary unit). (F) Cells transfected with RPS23R1 or control vector (Con) were lysed in 1% CHAPSO or 1% NP40 buffer. Lysates were incubated with mouse IgG (mIgG), rabbit IgG (rIgG), Myc antibody, or adenylate cyclase antibody. Immunoprecipitated proteins were subjected to SDS-PAGE and western blot analysis with adenylate cyclase or Myc (for RPS23R1) antibodies. In some experiments, protein levels were quantified by densitometry and normalized to those of controls for comparison (set as one arbitrary unit). Error bars indicate SEM. *p < 0.05, **p < 0.01. p values were calculated using two-tailed Student's t test (n = 3).
interaction between RPS23R1 and adenylate cyclases, enzymes responsible for cAMP synthesis (Kamenetsky et al., 2006) . Coimmunoprecipitation studies showed that RPS23R1 interacts with both overexpressed (data not shown) and endogenous ( Figure 6F ) adenylate cyclases in N2a cells overexpressing RPS23R1, suggesting a possible modulation of enzymatic activity for cAMP production.
To confirm that it is indeed the RPS23R1 protein rather than the Rps23r1 mRNA that mediates these effects, we constructed an RPS23R1 mutant vector with a stop codon at the beginning of the protein-coding region. Cells transfected with this mutant vector showed mRNA expression (detected by RT-PCR) but no protein expression of the mutant RPS23R1 ( Figure S6 ). In addition, overexpression of this mutant RPS23R1 did not affect the activity of PKA or GSK-3, or Ab levels ( Figure S6 ), excluding any potential RNA interfering effects arising from anti-sense interaction with Rps23 RNA.
Overexpression of RPS23R1 Reduces Ab Levels, GSK-3 Activity, and Tau Phosphorylation in the Brain of the Triple Transgenic AD Mice To validate RPS23R1 function in vivo, we generated an Rps23r1 transgenic mouse model specifically overexpressing Myctagged RPS23R1 in the brain. A transgenic expression cassette driven by the human Thy-1 promoter ( Figure S7A ) was microinjected into C57Bl6 mice and we used primers specifically amplifying exogenous Rps23r1 to genotype transgenic mice ( Figure S7B ). Reverse transcription-PCR revealed that mRNA of the exogenous gene was indeed expressed in transgenic mouse brains ( Figure S7C ). Protein expression of exogenous Myc-tagged RPS23R1 was also confirmed in brain tissues of transgenic mice ( Figure S7D ). In addition, immunoprecipitation/ western blot showed that total (including exogenous and endogenous) protein levels of RPS23R1 in the transgenic mice were about 2-fold higher than endogenous RPS23R1 levels in control mice ( Figure S7E ). We generated two mouse lines with similar RPS23R1 expression levels and results obtained from the two lines (including their crossing with 3XTg mice as described below) were similar. Herein we only presented results from line 2. Our results showed that levels of phosphorylated and therefore inactive GSK-3a/b were increased ( Figure S7D ), accompanied by reduced GSK-3b activity in Rps23r1 transgenic mouse brain ( Figure S7F ). Increased CREB phosphorylation indicative of upregulated PKA activity, as well as decreased phosphorylation of endogenous mouse brain tau, was also seen in Rps23r1 transgenic mouse brain ( Figure S7D ). In addition, preliminary observation detected no obvious aberrant behavioral phenotypes in Rps23r1 transgenic mice (data not shown).
We next crossed Rps23r1 transgenic mice with triple transgenic (3XTg) AD mice harboring mutations in human App (APP), Mapt (tau), and Psen1 (presenilin 1) genes (Oddo et al., 2003) . As expected, RPS23R1 overexpression in 3XTg mice dramatically increased the levels of cAMP and PKA activity ( Figure S8A ), resulting in elevated CREB activity, and reduced GSK-3 activity, tau phosphorylation, and Ab levels in mouse brains ( Figures 7A and S8B) . Consistently, the numbers of both Ab-immunostaining-positive (by Ab40-specific antibody and 6E10 antibody) and phosphorylated tau-immunostaining-positive (by PHF-1 and pT205 antibodies) neurons in the 3XTg mouse brain (both hippocampus and cortex) were significantly decreased following RPS23R1 overexpression ( Figures 7B, 7C , 7E, S8C, S8D, and S8F). Interestingly, protein levels of the synaptic marker PSD-95 were markedly increased following RPS23R1 overexpression in 3XTg mouse brains ( Figure 7A ). Immunostaining of PSD-95 ( Figures 7D and 7E ) and synapsin ( Figures S8E and S8F) , another synaptic marker, also revealed significantly higher immunoreactivity in the hippocampus of 3XTg mouse brains with RPS23R1 overexpression than that seen in 3XTg mice without RPS23R1. These results imply that RPS23R1 may rescue synapse impairment seen in 3XTg mice (Oddo et al., 2003) , in addition to, or as a consequence of, its effects on reducing Ab generation and tau phosphorylation. Consistent with the results found in cell cultures ( Figure S4B ), protein levels of ADAM10 and TACE were not affected by RPS23R1 overexpression in the brain of 3XTg mice ( Figure 7A ).
Caloric restriction and environmental enrichment have been shown to reduce AD-like pathologies and behavior deficits in animal models (Halagappa et al., 2007; Lazarov et al., 2005) . Since elevated CREB activity in the brain may affect animal behaviors such as food intake and daily activity, we compared body weight of RPS23R1-overexpressing mice to that of control mice and found no difference at 3 months of age. At 7 and 11 months of age, we noticed that RPS23R1-overexpressing mice are slightly (but not significantly) lighter than controls (data not shown), even though visual inspection of daily activity and food intake between these mice showed no obvious differences. Therefore, there is a possibility that RPS23R1 exerts its effect on alleviating AD-like pathologies by altering mouse behaviors and this possibility deserves further investigation.
DISCUSSION
Using the RHGP assay to screen for genes involved in regulating Ab generation, we identified the functional retroposed Rps23r1 gene on mouse chromosome 8. The RPS23R1 protein is a type Ib transmembrane protein and is expressed in the brain. In the present report, we provide compelling evidence to show that RPS23R1 overexpression can reduce both Ab levels and tau phosphorylation, two major pathological hallmarks of AD. We also reveal the underlying mechanism, i.e., RPS23R1 interacts with adenylate cyclases to upregulate cAMP levels, which activates PKA activity, hence inhibiting GSK-3 activity, tau phosphorylation, and Ab generation. These results elucidate an important link between adenylate cyclases and AD, which had not been illustrated previously.
Sequence analyses demonstrated that Rps23r1 originated through retroposition of mouse Rps23, which recruited regulatory units and additional protein encoding fragments at the retroposition site and became functional ( Figure 3A) . The reversal in transcriptional direction of Rps23r1 relative to the parental Rps23 gene explains why there is no protein sequence similarity between RPS23R1 and RPS23. Rps23 belongs to the ribosomal protein family and is highly conserved among species (Hori et al., 1993) . Since human ribosomal protein genes have been found to generate a large number of processed pseudogenes through retroposition (Zhang et al., 2002) , there is a possibility that human Figure 7 . RPS23R1 Overexpression Increases PKA Activity and Synapse Number and Reduces GSK-3b Activity, Tau Phosphorylation, and Ab Levels in Brains of 3XTg AD Mice (A) Brains from Rps23r1 transgenic mice and littermate controls (Con) on a 3XTg background at 11 months of age were dissected. One-half of the brain was lysed and analyzed for the levels of phosphorylated/total CREB, phosphorylated/total GSK-3, PSD-95, ADAM10, TACE, a-tubulin, and phosphorylated (PHF-1) and total tau forms by direct western blot. Ab and Myc-RPS23R1 were detected by immunoprecipitation-western blot using Ab antibody (6E10) and Myc antibody, respectively. *nonspecific band found specifically in 3XTg mouse brains. (B) The other half-brain from Con (I and III) and Rps23r1 transgenic (II and IV) mice was analyzed by immunohistochemistry for Ab using an Ab40-specific antibody. III and IV are higher magnifications of cortical regions from I and II, respectively. Red arrows indicate positive immunoreactivity. (C) Immunohistochemistry for phosphorylated tau (PHF-1 tau) was analyzed the same as in (B). Red arrows indicate positive immunoreactivity. (D) Immunohistochemistry for PSD-95 was analyzed the same as in (B), except that III and IV are higher magnifications of hippocampal regions from I and II, respectively. (E) Immunostained neurons (>400) in (B) and (C) were counted from five randomly selected cortical regions. Ratios of Ab40-positive and PHF-1 tau-positive neurons to total neurons were determined and normalized to those of control (Con) for comparison. The optical density (darkness) of PSD-95 staining in five randomly selected hippocampal regions were analyzed by the Photoshop software for comparison. *p < 0.05. p values were calculated using two-tailed Student's t test (n = 4). Error bars, SEM.
Rps23 may have also retroposed in humans and generated new functional genes with orientations and functions similar to those of Rps23r1. However, although we indeed identified several human Rps23 retroposition sites in the human genome ( Figure S1 ), neither computational gene prediction nor RT-PCR with primers binding adjacent regions of these human Rps23 retroposition sites has so far revealed any Rps23r1-like genes (data not shown). More extensive efforts are needed for screening functional Rps23r1 homologs in humans.
During aging, humans are susceptible to AD pathogenesis, typically characterized by Ab overproduction/aggregation and tau hyperphosphorylation. In contrast, wild-type mice rarely develop AD pathologies (De Strooper et al., 1995; Jankowsky et al., 2007; Johnstone et al., 1991) . The differences in AD susceptibility between humans and mice have been attributed to the sequence disparity between human and mouse Ab (and possibly tau) that underlie different aggregation properties (De Strooper et al., 1995; Jankowsky et al., 2007; Johnstone et al., 1991) , to the short lifespan of mice relative to humans (Jankowsky et al., 2004; Jankowsky et al., 2007) and to the differences in processing of human and mouse APP by BACE1 (Cai et al., 2001) . Should humans lack Rps23r1 homologs, our results would provide an alternative explanation, i.e., some genetic factors in mice, such as Rps23r1, protect them against an AD-like disease by preventing Ab over-production and tau hyperphosphorylation.
On the other hand, mouse RPS23R1 also exerts its functions in human cells, suggesting that RPS23R1-mediated signaling pathways are active in humans. Further scrutiny of these pathways, especially upstream events involving RPS23R1's effects on adenylate cyclases, is critical and underway. While it is not yet known whether there are functional homologs of RPS23R1 in humans, further elucidation of RPS23R1 functions and mechanism of action may prove to be important for developing new strategies for combating AD and other diseases including cancer and diabetes, in which the PKA and GSK-3 signaling pathways are centrally involved (Martinez et al., 2002; Naviglio et al., 2009) .
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents Maintenance of mouse neuroblastoma N2a cells, N2a cells stably expressing human APP Swedish mutation (N2aSwe), human HeLa cells stably expressing human APP Swedish mutation (HeLaSwe), and rat PC12 cells has been described (Lin et al., 2007; Wang et al., 2006; York et al., 2000) . PhoenixAmpho helper cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Antibodies used were: anti-Myc (9E10), anti-adenylate cyclases, anti-His, anti-ADAM10, and anti-TACE from Santa Cruz Biotechnology; anti-GSK-3a, anti-GSK-3b, anti-phospho-GSK3a/b (Ser21/9), anti-CREB, anti-phospho-CREB (Ser 133), anti-PSD-95, and anti-synapsin from Cell Signaling Technology; anti-Ab40, anti-pT205 tau and anti-total tau from Abcam; anti-Ab (6E10) from Covance; anti-tau-1 from Chemicon; anti-a-tubulin from Sigma; anti-PHF-1 tau from P. Davies at Albert Einstein School of Medicine; and the FCA18 antibody specifically recognizing the N terminus of APP bCTF from F. Checler at Institut de Pharmacologie Molecularie et Cellulaire du CNRS (Ancolio et al., 1999) . The rabbit polyclonal antibody 369 against the APP C terminus (Xu et al., 1997) and the anti-RPS23R1 antibody were developed in our laboratory. PKA inhibitor H89 and GSK-3 inhibitor lithium chloride were from Sigma.
Random Homozygous Gene Perturbation (RHGP) Strategy for Screening Ab-Reducing Genes
We constructed a new RHGP gene search vector from the original pLLGSV vector (Li and Cohen, 1996) . In the 3 0 LTR region of the new RHGP gene search vector, there is a sequence containing a puromycin N-acetyl-transferase gene (Pac), a TRE (tetracycline-regulated element, tet-off) regulated CMV promoter driving the Pac gene, a plasmid replication origin and a chloramphenicol resistance marker (Ori-CAT), and a LoxP site. In addition, there is a Cre recombinase gene (Cre) between the 5 0 LTR and the 3 0 LTR ( Figure 1A ). This new RHGP gene search vector was transfected into Phoenix-Ampho help cells. Generated infectious retrovirus in the cell culture supernatant was harvested and used to infect N2aSwe cells.
The infected N2aSwe cells with RHGP vector integration were selected with puromycin, live-stained with fluorescence-labeled APP bCTF antibody FCA18 (Ancolio et al., 1999) , and subjected to multiple rounds of FACS sorting for cells with accumulated cell surface APP bCTF. The positive-sorted cells were then treated with doxycycline (a derivative of tetracycline) and sorted for cells whose surface APP bCTF level was reversed back to background level in the presence of doxycycline. Resultant cells were cloned individually and assayed by ELISA and western blotting to confirm surface accumulation of APP bCTF and reduction of Ab generation. Positive candidate cell clones were further characterized and used for gene isolation.
Rps23r1 Gene Cloning
Genomic DNA was extracted from the FG01 RHGP cell clone, digested with restriction enzyme BamHI or HindIII, and self-ligated overnight with T4 ligase. The ligated DNA was precipitated, dissolved in TE buffer and electroporated into DH10B ElectroMax competent cells. The plasmid DNA from individual colonies was prepared for DNA sequencing. The target gene was identified by using UCSC Genome Browser Program.
Sequence Analyses
We blasted GenBank database with Rps23r1 cDNA sequence to explore its origin. Homologous sequences between Rps23r1 and mouse Rps23 were aligned manually. Sequence similarity between Rps23r1 and Rps23 sequences of humans, mice and rats were compared using their homologous regions. Potential transmembrane region in the RPS23R1 protein was predicted using PredictProtein (Rost et al., 2004) .
Membrane Fractionation
N2a cells were transfected with RPS23R1, APP, or SMAD3 expression vectors (all Myc tagged). After 48 hr, cells were washed with ice-cold phosphate-buffered saline, collected with homogenization buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 200 mM sucrose, 1 mM phenylmethylsulfonyl fluoride) and homogenized with a ball bearing cell cracker. Samples were centrifuged at 900 3 g for 10 min to remove cell debris and nuclei. Supernatants were centrifuged at 100,000 3 g for 60 min at 4 C. After transferring the supernatant (cytosol) to a new tube, the pellet was washed and resuspended with an equal volume (to that of cytosol) of homogenization buffer.
Biotinylation RPS23R1 transfected N2a cells were washed with ice-cold phosphate-buffered saline containing 1 mM each of CaCl 2 and MgCl 2 and incubated at 4 C with 0.5 mg/ml Sulfo-NHS-LC-biotin (Pierce) for 20 min and the process repeated once. Cell lysates were prepared in Nonidet P-40 lysis buffer. After affinity precipitation with streptavidin beads (Pierce), biotinylated proteins were eluted with SDS-PAGE sample buffer (Invitrogen) and loaded directly on SDS-PAGE gels for electrophoresis followed by western blot analysis with the Myc antibody.
Immunofluorescence Microscopy
For cell surface immunostaining of RPS23R1, N2a cells were first transfected with the Myc-RPS23R1-His 6 plasmid. Cells were then directly incubated with Myc or His6 antibody at 4 C for 2 hr, followed by washing, fixation, and permeabilization. In some experiments, cells were permeabilized before incubating with antibodies. Treated cells were incubated with Alexa Fluor 488-conjugated secondary antibody and DAPI. Specimens were examined and fluorescence images collected using a Zeiss fluorescence microscope with AxioVision software.
Ab ELISA Assay
HeLaSwe cells were transfected with RPS23R1 or control vector. Conditioned media and lysates from these cells were collected. The levels of Ab40 and Ab42 were quantified using ELISA kits (Invitrogen), following the manufacturer's protocols.
Pharmacological Treatments
N2aSwe cells were transfected with control vector or RPS23R1 and then equally split. Four hours before collection, cells were treated with the GSK-3 inhibitor lithium chloride (5 mM) or sodium chloride (5 mM, as control). Alternatively, cells were treated with a PKA inhibitor H89 (10 mM) or with DMSO for control.
Rps23r1 RNA Interference and Quantitative Real-Time PCR The mouse Rps23r1 siRNA used was: 5 0 -UACUGUUUGUCAUGCCACUUCU GAU-3 0 . The control siRNA was from Invitrogen. siRNA was transfected into N2a cells using Lipofectamine RNAiMAX reagent (Invitrogen), following the manufacturer's protocol. After Rps23r1 RNA interference, total RNA was extracted from N2a cells by Trizol reagent (Invitrogen). After reverse transcription into first strand cDNA using standard conditions, samples were analyzed independently by real-time PCR using an iCycler iQ with SYBR green supermix (Bio-Rad). The Rps23r1 primer pair used for real-time PCR was: Rps23r1-5 0 (5 0 -TGTTGCATACACATACATGC-3 0 ) and Rps23r1-3 0 (5 0 -TCATTAAGAACGG GAAGAAG-3 0 ). A pair of b-actin primers served as controls .
In Situ Hybridization
Histological sections from 2-month-old C57Bl6 mice were used for in situ hybridization reactions. Digoxygenin-labeled sense and antisense probes were generated for Rps23r1 (corresponding to nucleotides 1-641 of NM_001024728), and the hybridization signal was detected using an alkaline-phosphatase-conjugated anti-digoxygenin antibody and BCIP/NTB (Roche).
Crossing Brain-Specific Rps23r1 Transgenic Mice with 3XTg AD Mice We generated brain-specific Rps23r1 transgenic mice ( Figure S7 ). Hemizygous Rps23r1 transgenic mice were crossed with homozygous triple transgenic (3XTg) AD mice harboring mutations in human App and Mapt (tau) genes on a presenilin 1 (PS1) mutant background (Oddo et al., 2003) . Procedures involving animals and their care conformed to institutional guidelines (Animal Resources Department at Burnham Institute for Medical Research).
Immunohistochemistry and Data Analyses
Rps23r1/3XTg mice and littermate controls on a 3XTg background were sacrificed at 11 months of age. Half of the brain was used for immunoblot analysis and the other half was paraffin embedded for immunohistochemistry. Coronal brain sections (4 mm) were deparaffinized, hydrated, and then immunostained with anti-Ab antibodies (an anti-Ab40 specific antibody and 6E10), anti-phosphorylated tau antibodies (PHF-1 and pT205), or antibodies against PSD-95 and synapsin. After additional incubation with biotinylated secondary antibody, samples were incubated in ABC Elite (HRP) reagent (Vector Laboratories). Reactions were visualized by developing in DAB substrates (Vector Laboratories). All samples were visualized under a light microscope. For immunohistochemistry comparison of Ab and tau, immunostained neurons (>400) were counted from five randomly selected cortical regions. Ratios of Ab-positive and phosphorylated tau-positive neurons to total neurons were determined and normalized to those of controls. For immunohistochemistry comparison of synapse markers, five hippocampal regions were randomly selected and the images captured. After converting the images to grayscale, the optical density (darkness) of molecular layer staining was measured as an average of the gray value between white (0) and black (255) as described (Mathern et al., 1997) for comparison, by a computer-based image analysis using the Photoshop software.
In Vitro Activity Assays and cAMP Assay Commercial kits were used to assay in vitro activities of GSK-3b (Sigma) and PKA (Upstate). For GSK-3a activity, a commercial GSK-3b activity assay kit was used but the procedure to immunoprecipitate GSK-3b was replaced with immunoprecipitation of GSK-3a using an anti-GSK-3a antibody (Cell Signaling). cAMP levels were assayed using a commercial kit (Biovision).
Coimmunoprecipitation
Cells transfected with RPS23R1 were lysed in either CHAPSO buffer (1% CHAPSO, 25 mM HEPES [pH 7.4], 150 mM NaCl, and 2 mM EDTA supplemented with protease inhibitors) or in NP40 buffer (1% Nonidet P-40 in phosphate buffered saline, supplemented with protease inhibitors). Lysates were immunoprecipitated using mouse IgG, rabbit IgG, and antibodies against Myc or adenylate cyclases and Trueblot IP beads (eBioscience), followed by western blot with antibodies against Myc or adenylate cyclases.
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